Literature DB >> 11437655

Protection from immunodeficiency virus challenges in rhesus macaques by multicomponent DNA immunization.

J J Kim1, J S Yang, L K Nottingham, D J Lee, M Lee, K H Manson, M S Wyand, J D Boyer, K E Ugen, D B Weiner.   

Abstract

Multicomponent DNA vaccines were used to elicit immune responses, which can impact viral challenge in three separate rhesus macaque models. Eight rhesus macaques were immunized with DNA vaccines for HIV env/rev and SIV gag/pol and were challenged intravenously with 10 animal infective doses (AID(50)) of cell-free SHIV IIIB. Three of eight immunized rhesus macaques were protected, exhibiting no detectable virus. Animals protected from nonpathogenic SHIVIIIB challenge were rested for extended periods of time and were rechallenged first with pathogenic SIV(mac239) and subsequently with pathogenic SHIV89.6P viruses. Following the pathogenic challenges, all three vaccinated animals were negative for viral coculture and antigenemia and were negative by PCR. In contrast, the control animals exhibited antigenemia by 2 weeks postchallenge and exhibited greater than 10 logs of virus/10(6) cells in limiting dilution coculture. The control animals exhibited CD4 cell loss and developed SIV-related wasting with high viral burden and subsequently failed to thrive. Vaccinated animals remained virus-negative and were protected from the viral load, CD4 loss, disease, and death. We observed strong Th1-type cellular immune responses in the protected macaques throughout the study, suggesting their important roles in protection. These studies support the finding that multicomponent DNA vaccines can directly impact viral replication and disease in a highly pathogenic challenge system, thus potentially broadening our strategies against HIV. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11437655     DOI: 10.1006/viro.2001.0958

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  12 in total

1.  Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles.

Authors:  Gillis Otten; Mary Schaefer; Catherine Greer; Maria Calderon-Cacia; Doris Coit; Jina Kazzaz; Angelica Medina-Selby; Mark Selby; Manmohan Singh; Mildred Ugozzoli; Jan zur Megede; Susan W Barnett; Derek O'Hagan; John Donnelly; Jeffrey Ulmer
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

Review 2.  Expression library immunization: a road map for discovery of vaccines against infectious diseases.

Authors:  Adel M Talaat; Katherine Stemke-Hale
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

3.  Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques.

Authors:  Philip R Johnson; Bruce C Schnepp; Mary J Connell; Daniela Rohne; Suzanne Robinson; Georgia R Krivulka; Carol I Lord; Rebekah Zinn; David C Montefiori; Norman L Letvin; K Reed Clark
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins.

Authors:  Gillis R Otten; Mary Schaefer; Barbara Doe; Hong Liu; Indresh Srivastava; Jan zur Megede; Jina Kazzaz; Ying Lian; Manmohan Singh; Mildred Ugozzoli; David Montefiori; Mark Lewis; David A Driver; Thomas Dubensky; John M Polo; John Donnelly; Derek T O'Hagan; Susan Barnett; Jeffrey B Ulmer
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.

Authors:  John R Mascola; Mark G Lewis; Thomas C VanCott; Gabriela Stiegler; Hermann Katinger; Michael Seaman; Kristin Beaudry; Dan H Barouch; Birgit Korioth-Schmitz; Georgia Krivulka; Anna Sambor; Brent Welcher; Daniel C Douek; David C Montefiori; John W Shiver; Pascal Poignard; Dennis R Burton; Norman L Letvin
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

6.  Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus.

Authors:  Mattias N E Forsell; Yuxing Li; Maria Sundbäck; Krisha Svehla; Peter Liljeström; John R Mascola; Richard Wyatt; Gunilla B Karlsson Hedestam
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

7.  Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses.

Authors:  Yun Li; Bradley Cleveland; Igor Klots; Bruce Travis; Barbra A Richardson; David Anderson; David Montefiori; Patricia Polacino; Shiu-Lok Hu
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

8.  Simian immunodeficiency virus promoter exchange results in a highly attenuated strain that protects against uncloned challenge virus.

Authors:  Philippe Blancou; Nicole Chenciner; Raphaël Ho Tsong Fang; Valérie Monceaux; Marie-Christine Cumont; Denise Guétard; Bruno Hurtrel; Simon Wain-Hobson
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

9.  Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239.

Authors:  Helen Horton; Thorsten U Vogel; Donald K Carter; Kathy Vielhuber; Deborah H Fuller; Tim Shipley; James T Fuller; Kevin J Kunstman; Gerd Sutter; David C Montefiori; Volker Erfle; Ronald C Desrosiers; Nancy Wilson; Louis J Picker; Steven M Wolinsky; Chenxi Wang; David B Allison; David I Watkins
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccines.

Authors:  Jan zur Megede; Gillis R Otten; Barbara Doe; Hong Liu; Louisa Leung; Jeffrey B Ulmer; John J Donnelly; Susan W Barnett
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.